VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager program through a collaboration with ATUM. The partnership will apply ATUM's Leap-In Transposase(R) technology to generate stable clonal cell lines supporting IND/CTA-enabling activities and future clinical development. This milestone follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting and is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies.
VERAXA's BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional “AND”-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window. The collaboration with ATUM is a key step in advancing this innovative platform toward clinical trials.
The news is significant because it marks a transition from preclinical research to development activities necessary for regulatory filings. By initiating cell line development, VERAXA is laying the groundwork for manufacturing processes that will produce material for toxicology studies and, eventually, clinical trials. The use of ATUM's Leap-In Transposase technology aims to accelerate the generation of high-yielding, stable cell lines, which is critical for cost-effective and scalable production.
For more details, the full press release is available at https://ibn.fm/FCIlk. Additional information about VERAXA Biotech and its pipeline can be found in the company's newsroom at https://ibn.fm/VRXA.
The BiTAC platform represents a potential advancement in cancer immunotherapy by addressing a key limitation of current T-cell engagers: off-tumor toxicity. Conventional T-cell engagers can activate T cells in healthy tissues, leading to side effects that limit dosing. VERAXA's approach could expand the therapeutic window, making treatment more effective and tolerable. The initiation of cell line development is a crucial step toward bringing this therapy to patients.
Forward-looking statements in this article involve risks and uncertainties, including those described in the company's filings with the SEC. Investors should not place undue reliance on these statements, which are based on information available as of the date hereof. The company undertakes no duty to update this information unless required by law.
